🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Fiserv (FISV) to Report Q3 Earnings: What's in The Offing?

Published 10/21/2020, 10:40 PM
Updated 07/09/2023, 06:31 AM
FI
-
BAH
-
WCN
-
APTV
-

Fiserv (NASDAQ:FISV), Inc. FISV is scheduled to report third-quarter 2020 results on Oct 27, after the bell.

The company’s earnings missed the Zacks Consensus Estimate in the second quarter of 2020. The company delivered an earnings surprise of a negative 0.7% in the last four quarters, on average.

Expectations This Time Around

The Zacks Consensus Estimate for adjusted revenues is pegged at $3.56 billion, indicating growth of 13.8% from the year-ago quarter’s reported figure. The expected growth is likely to be driven by incremental revenues from the First Data acquisition which should aid the Acceptance, Payments and Corporate and Other segments.

Revenue growth and benefits of cost synergies are likely to have boosted Fiserv’s second-quarter 2020 earnings, the Zacks Consensus Estimate for which is pegged at $1.16 per share, indicating year-over-year growth of 13.7%.

What Our Model Says

Our proven model predicts an earnings beat for Fiserv this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Fiserv has an Earnings ESP of +3.86% and a Zacks Rank #3.

Fiserv, Inc. Price and EPS Surprise

Fiserv, Inc. Price and EPS Surprise

Fiserv, Inc. price-eps-surprise | Fiserv, Inc. Quote

Other Stocks That Warrant a Look

Aptiv (NYSE:APTV) APTV has an Earnings ESP of +15.51% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Booz Allen (NYSE:BAH) Hamilton BAH has an Earnings ESP of +3.64% and a Zacks Rank #3.

Waste Connections (NYSE:WCN) WCN has an Earnings ESP of +0.32% and a Zacks Rank #3.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases.

They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Fiserv, Inc. (FISV): Free Stock Analysis Report

Waste Connections, Inc. (WCN): Free Stock Analysis Report

Booz Allen Hamilton Holding Corporation (BAH): Free Stock Analysis Report

Aptiv PLC (APTV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.